Mucosal Cytokine Profiles After Induction Therapy With Granulocyte/Monocyte Apheresis in New Onset Inflammatory Colitis.

Granulocyte/Monocyte Apheresis (GMA) selectively removes circulating granulocytes and monocytes; important producers of pro-inflammatory cytokines. Seven children with new onset inflammatory bowel disease (IBD) colitis were treated with GMA together with mesalazine, and had significant decreases in PUCAI (p = 0.018) and Mayo endoscopic score (p = 0.013). We investigated the colonic mucosal cytokine profiles (CMCP) (analyzed with real-time polymerase chain reaction, (PCR)), before and after induction treatment, and in 6 non-IBD controls. Significant decreases were seen in CSF-2 (p = 0.018), TNF-[alpha] (p = 0.028), IL-23[alpha] (p = 0.043), IL-1[beta] (p = 0.028), IL-36[gamma] (p = 0.018), IL-10 (p = 0.028), and TGF[beta]1 (p = 0.043) after treatment. In 6 non-IBD controls there were significant lower levels of IL-12[beta] (p = 0.023) and IL-23[alpha] (p = 0.046) compared to the IBD patients at onset, and IL-22 (p = 0.088) and IL-36[gamma] (p = 0.062) showed lower values without reaching significant differences. We speculate that the decreases in CMCP after treatment may explain the observed clinical efficacy in the GMA treated IBD children. (C) 2017 by European Society for Pediatric Gastroenterology, Hepatology, and Nutrition and North American Society for Pediatric Gastroenterology,

from #ORL-AlexandrosSfakianakis via ola Kala on Inoreader http://ift.tt/2xnxeT8